In the last trading session, 3.22 million Rocket Pharmaceuticals Inc (NASDAQ:RCKT) shares changed hands as the company’s beta touched 0.89. With the company’s per share price at $6.50 changed hands at -$0.22 or -3.35% during last session, the market valuation stood at $700.30M. RCKT’s last price was a discount, traded about -315.08% off its 52-week high of $26.98. The share price had its 52-week low at $4.55, which suggests the last value was 30.0% up since then.
Analysts gave the Rocket Pharmaceuticals Inc (RCKT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.12. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended RCKT as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Rocket Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.54.
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) trade information
Instantly RCKT was in red as seen at the end of in last trading. With action -7.01%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -48.29%, with the 5-day performance at -7.01% in the red. However, in the 30-day time frame, Rocket Pharmaceuticals Inc (NASDAQ:RCKT) is 5.69% up.
The consensus price target for the stock as assigned by Wall Street analysts is 32, meaning bulls need an upside of 79.69% from its current market value. According to analyst projections, RCKT’s forecast low is 32 with 32 as the target high. To hit the forecast high, the stock’s price needs a -392.31% plunge from its current level, while the stock would need to soar -392.31% for it to hit the projected low.
Consensus estimates given by 11 financial analysts project the company’s revenue in the current quarter to hit an average of 4.36M. 10 analysts are of the opinion that Rocket Pharmaceuticals Inc’s revenue for the current quarter will be 250k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -11.60%. The 2025 estimates are for Rocket Pharmaceuticals Inc earnings to increase by 14.65%, but the outlook for the next 5-year period is at 43.25% per year.
RCKT Dividends
Rocket Pharmaceuticals Inc is expected to release its next quarterly earnings report in June.
WELLINGTON MANAGEMENT GROUP LLP holds the second largest percentage of outstanding shares, with 9.7665% or 9.16 million shares worth $197.12 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 7.6 shares estimated at $49.38 million under it, the former controlled 7.11% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.46% of the shares, roughly 2.62 shares worth around $17.04 million.
